Novartis will present results from more than 60 research studies, including investigator-initiated studies, at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress.

Primary results from ASC4FIRST, a pivotal Phase III study of Scemblix® (asciminib) versus standard tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib and bosutinib) in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-PC) will be presented at the official ASCO press program and at the EHA plenary session.

Despite the progress made, people with CML continue to struggle to find a treatment that is both effective and tolerable for them at the time of diagnosis and thereafter. We look forward to sharing the primary analysis of the pivotal Phase III ASC4FIRST study, which builds on our more than 20 years of experience in transforming CML care,' said Jeff Legos, Executive Vice President, Global Head of Oncology, Novartis.

"With these promising data, a new analysis of the NATALEE trial in patients with node-negative early-stage breast cancer, and further updates to our RLT portfolio, we continue our efforts to reimagine medicine for people with cancer, in partnership with the scientific community."

Copyright (c) 2024 All rights reserved.